The Clinical Trials Information Centre aims to give you information about what clinical trials are taking place that you may be eligible for. The search function below allows you to search by your location, your treatment stage and the stage of the trial. If you find a trial you think you may be eligible for, we suggest you print the information to take along to your next appointment with your clinical team as you will not be able to join the trial without the support of your clinical team.

In addition to the larger trials taking place in centres across the UK, there are sometimes phase I trials which have an even stricter entry criteria. We have not listed all of these but have instead listed where the phase I centres are so that you can ask your clinical team to contact them to find out if there’s any trials you may be eligible for.

This site will be updated regularly as trials are opening and closing in different locations all the time. Whilst we endeavour to keep it as up to date as we can, please always check with your clinical team about the availability of a trial in your area.

If you are confused about some of the terms and language used in the trial descriptions, use our glossary of terms used in clinical trials.

If you have any queries about the clinical trials information centre, you can call the Target Ovarian Cancer support line on 020 7923 5475 or email support@targetovariancancer.org.uk

Within
Miles of

Results list

The principal objective of the study is to look for changes in DNA methylation in ovarian tumours that occur after patients have received chemotherapy. The DNA methylation status of a panel of genes associated with drug resistance will be assessed in samples collected after patients have received chemotherapy, either at delayed primary surgery or interval debulking surgery or at the time that they present with relapsed disease. This will be compared with the methylation of the same genes in samples taken at first presentation, before any chemotherapy.
Trametinib is a drug that blocks a very important signal that controls the growth of cancer cells. It is thought that this signal is important in a variety of cancers, including low-grade serous ovarian and peritoneal cancers. Trametinib is experimental and has not yet been studied in patients with low-grade serous ovarian or peritoneal cancer. 
Researchers are looking for new ways to treat people with advanced cancer that is getting worse despite treatment. In this trial, they are looking at LY2940680 and a chemotherapy drug called paclitaxel. LY2940680 is a type of biological therapy called a cancer growth blocker. It stops signals that cancer cells use to divide and grow. The aims of the trial are to find the highest safe dose of LY2940680 to give with paclitaxel and to learn more about the side effects.
The aims of the trial are to: find the highest safe dose of pazopanib and fosbretabulin when the two drugs are given together learn more about the side effects of the drugs see whether pazopanib and fosbretabulin together work better than pazopanib alone. The trial is in two parts. The first part of the trial is to work out the best dose of both drugs to give. This involves three – six participants receiving doses of both drugs that are believed to be safe.
The researchers need about 588 people to take part worldwide and hope that around 50 people from the UK will take part. This trial is randomised and the people taking part are put into one of two groups: carboplatin and pegylated liposomal doxorubicin trabectedin and pegylated liposomal doxorubicin Your group is decided by a computer and neither you nor your doctor will be able to decide which group you are. If you are in the carboplatin and pegylated liposomal doxorubicin group, you will have treatment every four weeks.
TroVax helps the immune system to recognise and attack cancer cells. The aim of this trial is to find out if giving TroVax after a rise in CA125 (but before symptoms return) can slow the growth of cancer and delay the start of chemotherapy.  Treatment lasts 11 months and this will include approximately 12 visits to hospital. 
Doctors usually treat ovarian cancer with surgery followed by chemotherapy. The chemotherapy often includes a platinum drug such as carboplatin. If your cancer gets worse within six months of having this treatment, it is called platinum resistant. You may then have treatment with a taxane chemotherapy drug called paclitaxel. But sometimes the cancer starts to grow again. So researchers are looking at ways to delay this. In this trial, they are looking at AZD2014. It is a type of biological therapy. It is a cancer growth blocker. It stops signals that cancer cells use to divide and grow.
The aims of the trial are to:  Find the best dose of EnAd that you can have directly into your tummy, both on its own and alongside paclitaxel   Learn more about the side effects of EnAd   Find out more about what happens to EnAd in the body  See if the combination of EnAd and paclitaxel helps women with ovarian cancer The trial is in two parts. The researchers need up to 47 women to take part and all participants will be given EnAd. EnAd conists of parts of viruses that have been made to kill cancer cells but not affect normal cells. 
This trial looks at whether women who have completed chemotherapy for ovarian cancer, fallopian tube cancer or primary peritoneal cancer benefit from a short course of psychological support immediately following their treatment. The course of support is provided in three sessions at local Maggie’s Centres. 
This trial is for women who delay having surgery. Instead, surveillance with a 4 monthly blood test (ROCA) is carried out. This could be a reassuring option until they are ready for surgery.  Their blood will be tested for CA-125, a protein which increases in cases of ovarian cancer. The result of the CA-125 is then analysed by the ROCA Test, which tells how likely it is that they currently have an ovarian cancer. The ROCA Test calculates their risk, by looking at age, menopause status and previous CA-125 levels if there are any.
This trial is looking at whether this additional drug treatment improves progression free survival (the length of time during and after treatment that a patient lives with the disease but it does not get worse) in women with stage III / IV high grade serous epithilial ovarian cancer.  It is a three arm trial: 
They will collect samples from women with ovarian cancer over time, to look at differences between tumours that come back after chemotherapy compared to when they were first diagnosed. This may help them understand why tumours stop responding (become resistant) to chemotherapy. They may also find ways of predicting which tumours will respond to chemotherapy.
This trial is looking at whether the additional drug treatment of avelumab alongside platinum based chemotherapy improves progression free survival (the length of time during and after treatment that a woman lives with the disease but it does not get worse) in women with stage III / IV disease at diagnosis. It is a three arm trial:
A randomized, double-blind, placebo-controlled, phase 2 study to assess the efficacy and safety of farletuzumab (MORAb 003) in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (PLD) in subjects with low CA125 platinum-sensitive ovarian cancer.
Clear cell cancer is a rare type of cancer. If it starts in the ovary or the lining of the womb (endometrium), doctors often treat it with surgery followed by chemotherapy. But sometimes the cancer can continue to grow or come back after treatment. In this situation chemotherapy is not always helpful and so researchers are looking for new treatments. In this trial they are looking at a drug called nintedanib.
The study aims to recruit approximately 275 patients   Patients will receive olaparib as an oral medication at a dose of 400mg twice a day.
This is a three arm trial, both phase I and phase II dependent upon the arm that the woman is randomised to: Phase Ib: APR-246 + Carboplatin/Caelyx. Phase II: Arm A. APR-246 + Carboplatin/Caelyx Phase II: Arm B. Carboplatin/Caelyx    
The study will assess the efficacy of niraparib as maintenance treatment. This study is a randomized study in patients with stage III or IV ovarian cancer. It is double-blind so neither the doctor nor the patient will know if they are on Niraparib or the placebo.
The aims of the trial are to: Help diagnose ovarian cancer earlier when treatment is likely to work better Help identify which women need further investigations for possible ovarian cancer and reduce unnecessary tests, hospital visits and distress in women who do not have ovarian cancer The researchers hope that the information they collect will help to improve diagnosis for women with ovarian cancer in the future.
At present the precise level of benefit obtained from removing the tubes alone is not known. There are no research studies to show whether this ‘two-stage procedure’ is acceptable and effective at preventing ovarian cancer. Further research is needed to establish this. This study is about completing a survey to understand women's views on this ‘two-stage’ strategy to prevent ovarian cancer. 
This is a Phase I non-randomised international multi-site trial for advanced solid tumours. For male or females. (Not exclusive to ovarian cancer.). The purpose of this first-in-human study is to evaluate the safety and tolerability of escalating doses of ODM-203 in subjects with advanced solid tumours and to determine the maximum tolerated dose and dose limiting toxicities.
The primary aim of this study is to evaluate the impact of surgery on patients quality of life and progression free survival at short (4- 6 weeks), medium term (6 months, 12 months) and long term (18 months, 24 months) using questionnaires in patients undergoing standard or extensive surgery for Stage IIIC/IV ovarian cancer.
To compare the overall survival (OS) after primary debulking surgery (PDS) versus interval debulking surgery (IDS) following neoadjuvant chemotherapy (NACT) in patients with FIGO (2014) stage IIIB-IVB ovarian, tubal, and peritoneal carcinoma.